Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2018-09-14 | Reverse | 1:30 |
| 2017-05-05 | Forward | 10:1 |
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing treatments for obesity, liver diseases, and hepatitis B, with lead candidates including pemvidutide and HepTcell.
Pemvidutide, Altimmune's lead investigational peptide-based GLP-1/glucagon dual receptor agonist, is in late-stage trials for MASH and obesity, and is also being studied for alcohol use disorder and alcohol-associated liver disease.
On June 26, 2025, Altimmune announced topline results from its IMPACT Phase 2b trial of pemvidutide for MASH. While the company highlighted positive aspects, a key endpoint for fibrosis improvement was not statistically significant, leading to a 53.18% drop in stock price on the same day. This significant negative market reaction prompted an investigation by law firm Pomerantz LLP on behalf of investors concerning potential securities fraud or other unlawful business practices.
Altimmune announced a CEO succession plan to transition the company from a clinical-stage to a late-stage clinical and commercial-focused entity. The incoming CEO, Jerry Durso, brings extensive experience in leading liver disease-focused companies through clinical growth and commercialization, signaling a strategic pivot towards bringing its lead candidate, pemvidutide, to market.
Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or ALD.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 VIR | $11.06 | COMPARE |
 GPCR | $25.30 | COMPARE |
 LBRX | $34.28 | COMPARE |
 ANRO | $23.86 | COMPARE |
 ABUS | $4.17 | COMPARE |
 ANNX | $4.06 | COMPARE |
 AURA | $6.16 | COMPARE |
 ASMB | $22.67 | COMPARE |
